Aligos Therapeutics (ALGS) Equity Ratio (2021 - 2025)
Aligos Therapeutics' Equity Ratio history spans 5 years, with the latest figure at 0.6 for Q4 2025.
- For Q4 2025, Equity Ratio rose 246.32% year-over-year to 0.6; the TTM value through Dec 2025 reached 0.6, up 246.32%, while the annual FY2025 figure was 0.6, 246.32% up from the prior year.
- Equity Ratio reached 0.6 in Q4 2025 per ALGS's latest filing, down from 0.65 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.83 in Q1 2021 to a low of 0.41 in Q4 2024.
- Average Equity Ratio over 5 years is 0.64, with a median of 0.7 recorded in 2023.
- Peak YoY movement for Equity Ratio: plummeted 168.02% in 2024, then soared 246.32% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.78 in 2021, then dropped by 9.76% to 0.71 in 2022, then fell by 14.2% to 0.61 in 2023, then tumbled by 168.02% to 0.41 in 2024, then skyrocketed by 246.32% to 0.6 in 2025.
- Per Business Quant, the three most recent readings for ALGS's Equity Ratio are 0.6 (Q4 2025), 0.65 (Q3 2025), and 0.76 (Q2 2025).